Morphine-3-glucuronide--a potent antagonist of morphine analgesia
- PMID: 2402182
- DOI: 10.1016/0024-3205(90)90619-3
Morphine-3-glucuronide--a potent antagonist of morphine analgesia
Abstract
In this study, morphine-3-glucuronide (M3G), the major plasma and urinary metabolite of morphine, was shown to be a potent antagonist of morphine analgesia when administered to rats by the intra-cerebroventricular (i.c.v.) route. The antagonism of morphine analgesia was observed irrespective of whether i.c.v. M3G (2.5 or 3.0 micrograms) was administered 15 mins prior to or 15 mins after i.c.v. morphine (20 micrograms). When M3G (10mg) was administered intraperitoneally (i.p.) to rats 30-40 mins prior to morphine (1.5mg i.p.), the analgesic response was significantly reduced compared to administration of morphine (1.5mg i.p.) alone. It was further demonstrated that i.c.v. M3G (2.0 micrograms) antagonized the analgesic effects of subsequently administered i.c.v. morphine-6-glucuronide (0.25 micrograms).
Similar articles
-
Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat.Pain. 1992 Feb;48(2):249-255. doi: 10.1016/0304-3959(92)90065-J. Pain. 1992. PMID: 1589243
-
Intrathecal morphine-3-glucuronide does not antagonize spinal antinociception by morphine or morphine-6-glucuronide in rats.Eur J Pharmacol. 1993 Nov 9;249(2):247-50. doi: 10.1016/0014-2999(93)90441-j. Eur J Pharmacol. 1993. PMID: 8287909
-
The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complex.Life Sci. 1994;54(10):687-94. doi: 10.1016/0024-3205(94)00552-4. Life Sci. 1994. PMID: 8107513
-
[Study of Supplementary Analgesics Capable of Reducing the Dosage of Morphine].Yakugaku Zasshi. 2016;136(2):329-35. doi: 10.1248/yakushi.15-00242. Yakugaku Zasshi. 2016. PMID: 26831810 Review. Japanese.
-
[Analgesic effect of morphine and its metabolites administered by an intracerebroventricular route].Bull Acad Natl Med. 1995 Jun;179(6):1237-52; discussion 1252-3. Bull Acad Natl Med. 1995. PMID: 8542351 Review. French.
Cited by
-
Intranasal delivery--modification of drug metabolism and brain disposition.Pharm Res. 2010 Jul;27(7):1208-23. doi: 10.1007/s11095-010-0127-5. Epub 2010 Apr 6. Pharm Res. 2010. PMID: 20372990
-
Pharmacokinetics of opioids in liver disease.Clin Pharmacokinet. 1999 Jul;37(1):17-40. doi: 10.2165/00003088-199937010-00002. Clin Pharmacokinet. 1999. PMID: 10451781 Review.
-
Paradoxical pain.BMJ. 1993 Mar 20;306(6880):793. doi: 10.1136/bmj.306.6880.793-a. BMJ. 1993. PMID: 8490355 Free PMC article. No abstract available.
-
Pain treatment in multimorbid patients, the older population and other high-risk groups. The clinical challenge of reducing toxicity.Drug Saf. 1998 Jun;18(6):457-72. doi: 10.2165/00002018-199818060-00006. Drug Saf. 1998. PMID: 9638390 Review.
-
A successful case in cancer pain management with high-dose intravenous morphine.J Anesth. 1995 Dec;9(4):374-5. doi: 10.1007/BF02479958. J Anesth. 1995. PMID: 23839893 No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources